After a decade of outpacing the market, are we finally going to see a plateau in the growth of orphan drugs? Well, maybe. Data-wise, there’s only a hint of that being the case, but there are some significant headwinds for companies developing these treatments for rare diseases. The Inflation Reduction Act (IRA) combined with successes across more common conditions with potentially huge markets may see some of the biggest players start pump R&D resources elsewhere. 

In this article we take a quick look at the current state of the orphan drugs market, the challenges on the horizon and some of the key data points in this unique portion of the pharma industry. 



Will the impending patent cliff prompt a shift away from orphans?
What are the unintended consequences of the IRA?
What will the orphan market look like in 2028?
Who will be leading the charge in orphans towards the end of the decade?